What is William Blair’s Estimate for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at William Blair lifted their FY2024 earnings per share estimates for shares of Tenax Therapeutics in a research report issued on Wednesday, November 13th. William Blair analyst M. Phipps now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.60) for the year, up from their previous forecast of ($6.90). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($1.03) EPS.

TENX has been the subject of a number of other research reports. StockNews.com assumed coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating for the company. Leerink Partners assumed coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. Guggenheim assumed coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target for the company. Finally, Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Trading Down 0.8 %

TENX stock opened at $4.83 on Monday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $33.44. The business has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $3.70.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TENX. Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth approximately $288,000. Stonepine Capital Management LLC purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth approximately $173,000. Finally, Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth approximately $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.